Ganirelix (CAS 124904-93-4) – Research Grade is a high-purity chemical compound.

Ganirelix is a polypeptide.

Research Context

Research Applications

Ganirelix is primarily studied for its role in reproductive health, particularly in the context of controlled ovarian stimulation during assisted reproductive technology (ART) procedures. This peptide is utilized to prevent premature ovulation, allowing for better timing of egg retrieval. It has been particularly significant in the areas of infertility treatment and in protocols for in vitro fertilization (IVF).

Ganirelix has no FDA-approved trade name; however, it is often referenced in clinical settings as part of the standard protocol for ART. Research indicates its potential applications in other therapeutic areas, including hormonal regulation and endocrine disorders.

History & Development

Ganirelix was developed by the pharmaceutical company Organon, which focused on creating effective gonadotropin-releasing hormone (GnRH) antagonists. The peptide was introduced in the late 1990s and received regulatory approval for clinical use in 2000. Since then, it has become a staple in fertility treatments, especially in Europe and other regions.

One of the notable design features of Ganirelix is its resistance to enzymatic degradation, which enhances its efficacy and bioavailability. This structural modification allows for a more prolonged action compared to native GnRH.

Mechanism of Action

Ganirelix functions as a competitive antagonist of the GnRH receptor, which is located in the pituitary gland. By binding to these receptors, Ganirelix inhibits the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), hormones that are crucial for ovulation and follicular development. This blockade prevents premature luteinization and allows for better control over the ovarian stimulation process during ART.

The downstream effects of Ganirelix's action result in a more synchronized follicular development, improving the chances of successful egg retrieval and fertilization during IVF procedures.

Clinical Data

Clinical studies, such as those conducted by Humaidan et al., have demonstrated the efficacy of Ganirelix in controlled ovarian stimulation. In a Phase 3 trial, it was observed that the use of Ganirelix resulted in improved outcomes in terms of oocyte retrieval rates compared to traditional protocols without GnRH antagonists. Additionally, published studies suggest that Ganirelix effectively reduces the risk of ovarian hyperstimulation syndrome (OHSS), a serious complication associated with fertility treatments.

Another study, led by Dr. M. L. B. A. Al-Inany, further supports these findings, highlighting the peptide's safety and effectiveness in various patient populations undergoing IVF.

How It Compares

Ganirelix is often compared to other GnRH antagonists and agonists used in fertility treatments, such as Cetrorelix and Leuprolide. Cetrorelix shares a similar mechanism of action, also inhibiting LH and FSH release, but may have different pharmacokinetic profiles and dosing regimens. In contrast, Leuprolide, a GnRH agonist, initially stimulates the release of these hormones before eventually suppressing them, which can lead to a different clinical approach in managing ovarian stimulation.

While Ganirelix and Cetrorelix are both used to prevent premature ovulation, Ganirelix is often favored for its rapid onset of action and shorter half-life, which allows for more precise control over the timing of ovulation induction.

Solubility & Storage

Ganirelix is typically reconstituted using sterile water for injection or bacteriostatic water. Once reconstituted, it should be stored at a temperature of 2-8 degrees Celsius (36-46 degrees Fahrenheit) and is generally stable for up to 28 days when refrigerated. The lyophilized form of Ganirelix should be stored in a cool, dry place, away from light, to maintain its stability until reconstitution.

Future Research Directions

Future research involving Ganirelix is exploring its potential applications beyond fertility treatments. Emerging studies are investigating its role in addressing hormonal imbalances and conditions such as polycystic ovary syndrome (PCOS). Additionally, there is growing interest in its potential off-label uses in managing other endocrine disorders.

Researchers are also examining the long-term effects of Ganirelix on ovarian function and its implications for women's health, particularly in populations experiencing infertility or other reproductive challenges.